APA

Barone F. C., Irving E. A., Ray A. M., Lee J. C., Kassis S., Kumar S., Badger A. M., White R. F., McVey M. J., Legos J. J., Erhardt J. A., Nelson A. H., Ohlstein E. H., Hunter A. J., Ward K., Smith B. R., Adams J. L. & Parsons A. A. (20010405). SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. : The Journal of pharmacology and experimental therapeutics.

Chicago

Barone F C, Irving E A, Ray A M, Lee J C, Kassis S, Kumar S, Badger A M, White R F, McVey M J, Legos J J, Erhardt J A, Nelson A H, Ohlstein E H, Hunter A J, Ward K, Smith B R, Adams J L and Parsons A A. 20010405. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. : The Journal of pharmacology and experimental therapeutics.

Harvard

Barone F. C., Irving E. A., Ray A. M., Lee J. C., Kassis S., Kumar S., Badger A. M., White R. F., McVey M. J., Legos J. J., Erhardt J. A., Nelson A. H., Ohlstein E. H., Hunter A. J., Ward K., Smith B. R., Adams J. L. and Parsons A. A. (20010405). SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. : The Journal of pharmacology and experimental therapeutics.

MLA

Barone F C, Irving E A, Ray A M, Lee J C, Kassis S, Kumar S, Badger A M, White R F, McVey M J, Legos J J, Erhardt J A, Nelson A H, Ohlstein E H, Hunter A J, Ward K, Smith B R, Adams J L and Parsons A A. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. : The Journal of pharmacology and experimental therapeutics. 20010405.